Fatty acid-binding protein 4: a key regulator of ketoacidosis in new-onset type 1 diabetes
- PMID: 34806114
- DOI: 10.1007/s00125-021-05606-0
Fatty acid-binding protein 4: a key regulator of ketoacidosis in new-onset type 1 diabetes
Abstract
Aims/hypothesis: Fatty acid-binding protein 4 (FABP4) is an adipokine with a key regulatory role in glucose and lipid metabolism. We prospectively evaluated the role of FABP4 in the pathophysiology of diabetic ketoacidosis (DKA) in new-onset type 1 diabetes.
Methods: Clinical and laboratory data were prospectively collected from consecutive children presenting with new-onset type 1 diabetes. In addition to blood chemistry and gases, insulin, C-peptide, serum FABP4 and NEFA were collected upon presentation and 48 h after initiation of insulin treatment. In a mouse model of type 1 diabetes, glucose, insulin, β-hydroxybutyrate and weight were compared between FABP4 knockout (Fabp4-/-) and wild-type (WT) mice.
Results: Included were 33 children (mean age 9.3 ± 3.5 years, 52% male), of whom 14 (42%) presented with DKA. FABP4 levels were higher in the DKA group compared with the non-DKA group (median [IQR] 10.1 [7.9-14.2] ng/ml vs 6.3 [3.9-7] ng/ml, respectively; p = 0.005). The FABP4 level was positively correlated with HbA1c at presentation and inversely correlated with venous blood pH and bicarbonate levels (p < 0.05 for all). Following initiation of insulin therapy, a marked reduction in FABP4 was observed in all children. An FABP4 level of 7.22 ng/ml had a sensitivity of 86% and a specificity of 78% for the diagnosis of DKA, with an area under the receiver operating characteristic curve of 0.78 (95% CI 0.6, 0.95; p = 0.008). In a streptozotocin-induced diabetes mouse model, Fabp4-/- mice exhibited marked hypoinsulinaemia and hyperglycaemia similar to WT mice but displayed no significant increase in β-hydroxybutyrate and were protected from ketoacidosis.
Conclusions/interpretation: FABP4 is suggested to be a necessary regulator of ketogenesis in insulin-deficient states.
Keywords: Adipokine; DKA; FABP4; Fatty acid-binding protein; Ketogenesis; Type 1 diabetes; aP2.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7(6):489–503. https://doi.org/10.1038/nrd2589 - DOI - PubMed - PMC
-
- Hotamisligil GS, Bernlohr DA (2015) Metabolic functions of FABPs - mechanisms and therapeutic implications. Nat Rev Endocrinol 11:592–605. https://doi.org/10.1038/nrendo.2015.122 - DOI - PubMed - PMC
-
- Ertunc ME, Sikkeland J, Fenaroli F et al (2015) Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res 56(2):423–434. https://doi.org/10.1194/jlr.M055798 - DOI - PubMed - PMC
-
- Mita T, Furuhashi M, Hiramitsu S et al (2015) FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring) 23(2):359–367. https://doi.org/10.1002/oby.20954 - DOI
-
- Syamsunarno MRAA, Iso T, Hanaoka H et al (2013) A critical role of fatty acid binding protein 4 and 5 (FABP4/5) in the systemic response to fasting. PLoS One 8(11):e79386. https://doi.org/10.1371/journal.pone.0079386 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous